Lv1
78 积分 2024-07-15 加入
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD
11天前
已完结
Post-transplant cyclophosphamide at 80 mg/kg with low dose post-engraftment anti-thymocyte globulin in haploidentical transplantation with myeloablative conditioning
3个月前
已完结
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party
3个月前
已完结
Dose Effect of Antithymocyte Globulin or Post-transplant Cyclophosphamide in Haploidentical Peripheral Blood Stem Cell Transplantation: A Comparative Study
3个月前
已完结
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
4个月前
已完结
Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling
4个月前
已完结
Inflammation and myeloproliferative neoplasms
4个月前
已完结
A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis
4个月前
已完结
JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
4个月前
已完结
A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis
4个月前
已完结
皖公网安备34019202002308
